Quantification and reliability of [

Lungs Muscarinic acetylcholine receptors Positron emission tomography Test-retest [11C]VC-002

Journal

EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946

Informations de publication

Date de publication:
03 Jun 2020
Historique:
received: 15 01 2020
accepted: 22 04 2020
entrez: 5 6 2020
pubmed: 5 6 2020
medline: 5 6 2020
Statut: epublish

Résumé

The radioligand [ PET measurements using [ The 1TCM was the statistically preferred model for description of [ The kinetic behaviour and good repeatability of [ ClinicalTrials.gov identifier: NCT03097380, registered: 31 March 2017.

Sections du résumé

BACKGROUND BACKGROUND
The radioligand [
METHODS METHODS
PET measurements using [
RESULTS RESULTS
The 1TCM was the statistically preferred model for description of [
CONCLUSIONS CONCLUSIONS
The kinetic behaviour and good repeatability of [
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov identifier: NCT03097380, registered: 31 March 2017.

Identifiants

pubmed: 32495011
doi: 10.1186/s13550-020-00634-0
pii: 10.1186/s13550-020-00634-0
pmc: PMC7270393
doi:

Banques de données

ClinicalTrials.gov
['NCT03097380']

Types de publication

Journal Article

Langues

eng

Pagination

59

Références

Br J Pharmacol Chemother. 1965 Aug;25(1):4-17
pubmed: 19108209
J Nucl Med. 2007 Feb;48(2):207-13
pubmed: 17268016
J Manag Care Pharm. 2005 Jun;11(5 Suppl A):S2-13; quiz S14-6
pubmed: 15934804
J Cereb Blood Flow Metab. 2002 Oct;22(10):1271-81
pubmed: 12368666
J Nucl Med. 1999 Aug;40(8):1270-6
pubmed: 10450677
Pharmacol Rev. 2012 Jul;64(3):450-504
pubmed: 22611179
Trends Pharmacol Sci. 2006 Jun;27(6):310-6
pubmed: 16678917
EJNMMI Res. 2019 Jan 29;9(1):9
pubmed: 30694407
Acta Oncol. 2015;54(8):1105-12
pubmed: 25833329
Curr Radiopharm. 2020;13(3):185-194
pubmed: 31868150
Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):301-7
pubmed: 24006152
Eur Respir J. 2003 Apr;21(4):567-73
pubmed: 12762337
J Cereb Blood Flow Metab. 1989 Oct;9(5):696-708
pubmed: 2528555
Am J Respir Crit Care Med. 2009 Sep 15;180(6):533-9
pubmed: 19574441
J Cereb Blood Flow Metab. 1996 Sep;16(5):834-40
pubmed: 8784228
Psychiatry Res. 1996 Oct 7;67(3):163-71
pubmed: 8912956
Clin Pharmacol Ther. 1995 Mar;57(3):309-17
pubmed: 7697948
Chest. 2005 Oct;128(4):3020-7
pubmed: 16236982
J Cereb Blood Flow Metab. 1996 Jan;16(1):42-52
pubmed: 8530554
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
J Nucl Med. 2000 Oct;41(10):1603-11
pubmed: 11037987
J Cereb Blood Flow Metab. 2000 Jul;20(7):1111-33
pubmed: 10908045
Eur J Nucl Med Mol Imaging. 2011 May;38(5):832-42
pubmed: 21210109
Am J Respir Crit Care Med. 1996 Nov;154(5):1277-83
pubmed: 8912736
EJNMMI Res. 2017 Dec;7(1):47
pubmed: 28547129
J Med Chem. 1997 Jan 3;40(1):117-24
pubmed: 9016336
Neuroimage. 2017 Jul 15;155:344-353
pubmed: 28419852
Clin Cancer Res. 2013 Jan 1;19(1):183-93
pubmed: 23136193
Respir Care. 2007 Jul;52(7):833-51
pubmed: 17594728
J Nucl Med. 2017 Feb;58(2):201-207
pubmed: 28082432
J Cereb Blood Flow Metab. 2002 Dec;22(12):1425-39
pubmed: 12468888
Am Rev Respir Dis. 1990 Jun;141(6):1559-68
pubmed: 2350099
Mol Pharmacol. 1966 Jul;2(4):352-9
pubmed: 5968075

Auteurs

Zsolt Cselényi (Z)

PET Science Centre, Precision Medicine, R&D, AstraZeneca, Stockholm, Sweden. Zsolt.Cselenyi@astrazeneca.com.
Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden. Zsolt.Cselenyi@astrazeneca.com.

Aurelija Jucaite (A)

PET Science Centre, Precision Medicine, R&D, AstraZeneca, Stockholm, Sweden.
Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Cecilia Kristensson (C)

BioPharmaceuticals R&D, AstraZeneca, Göteborg, Sweden.

Per Stenkrona (P)

Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Pär Ewing (P)

BioPharmaceuticals R&D, AstraZeneca, Göteborg, Sweden.

Andrea Varrone (A)

Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Peter Johnström (P)

PET Science Centre, Precision Medicine, R&D, AstraZeneca, Stockholm, Sweden.
Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Magnus Schou (M)

PET Science Centre, Precision Medicine, R&D, AstraZeneca, Stockholm, Sweden.
Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Ana Vazquez-Romero (A)

Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Mohammad Mahdi Moein (MM)

Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Martin Bolin (M)

Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.

Jonathan Siikanen (J)

Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.

Pär Grybäck (P)

Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.

Bengt Larsson (B)

BioPharmaceuticals R&D, AstraZeneca, Göteborg, Sweden.

Christer Halldin (C)

Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Ken Grime (K)

BioPharmaceuticals R&D, AstraZeneca, Göteborg, Sweden.

Ulf G Eriksson (UG)

BioPharmaceuticals R&D, AstraZeneca, Göteborg, Sweden.

Lars Farde (L)

PET Science Centre, Precision Medicine, R&D, AstraZeneca, Stockholm, Sweden.
Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Classifications MeSH